Stockscreener 앱 받기
16.27
1.45%
-0.24
시장 영업 전:
16.40
0.13
+0.80%
전일 마감가:
$16.51
열려 있는:
$16.66
하루 거래량:
1.19M
Relative Volume:
0.76
시가총액:
$2.54B
수익:
$340.81M
순이익/손실:
$-419.65M
주가수익비율:
-5.7088
EPS:
-2.85
순현금흐름:
$-402.10M
1주 성능:
-3.56%
1개월 성능:
-8.80%
6개월 성능:
+9.19%
1년 성능:
-21.93%
1일 변동 폭
$15.69
$16.68
1주일 범위
$15.69
$16.91
52주 변동 폭
$10.57
$24.34
Denali Therapeutics Inc Stock (DNLI) Company Profile
명칭
Denali Therapeutics Inc
전화
(650) 866-8547
주소
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
DNLI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
16.27 | 2.58B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 재개 | Morgan Stanley | Overweight |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2025-01-07 | 개시 | Robert W. Baird | Outperform |
| 2025-01-03 | 개시 | William Blair | Outperform |
| 2024-12-16 | 업그레이드 | Stifel | Hold → Buy |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 개시 | B. Riley Securities | Buy |
| 2023-01-30 | 개시 | SVB Securities | Outperform |
| 2022-12-05 | 개시 | Cowen | Outperform |
| 2022-11-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-02 | 개시 | BofA Securities | Buy |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-09-21 | 개시 | Oppenheimer | Outperform |
| 2021-09-01 | 개시 | SMBC Nikko | Outperform |
| 2021-05-18 | 개시 | UBS | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-02-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-02-24 | 개시 | Jefferies | Buy |
| 2020-02-19 | 개시 | Stifel | Hold |
| 2020-01-27 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-26 | 개시 | Wedbush | Neutral |
| 2019-09-13 | 개시 | Nomura | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 개시 | Janney | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 개시 | Goldman | Neutral |
| 2018-01-02 | 개시 | JP Morgan | Overweight |
| 2018-01-02 | 개시 | Morgan Stanley | Overweight |
모두보기
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study - MSN
Smart Money: Is Denali Therapeutics Inc stock recession proofM&A Rumor & Daily Technical Stock Forecast Reports - moha.gov.vn
Hunter Syndrome Treatment Market is expected to reach US$ - openPR.com
Denali’s Hunter syndrome therapy shows promise in Phase 1/2 trial - Investing.com Nigeria
Understanding Momentum Shifts in (DNLI) - Stock Traders Daily
Denali Therapeutics stock holds Buy rating at Jefferies on FDA approval confidence - Investing.com Nigeria
Denali’s Hunter syndrome therapy shows promise in Phase 1/2 trial By Investing.com - Investing.com South Africa
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - The Manila Times
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - GlobeNewswire Inc.
Denali Therapeutics Earnings Notes - Trefis
Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500
3 Biotech Stocks With Major 2026 Catalysts - Nasdaq
Denali Therapeutics clears technical benchmark, hitting 80-plus RS rating - MSN
What drives Denali Therapeutics Inc 4DN stock priceIPO Market Watch & Free Expert Stock Watchlists - earlytimes.in
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
BTIG reiterates Denali Therapeutics (DNLI) buy recommendation - MSN
Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions - Yahoo Finance
How Investors May Respond To Denali Therapeutics (DNLI) $200 Million Equity Raise And FDA Voucher Talks - Yahoo Finance
Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? - Insider Monkey
Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN
What risks investors should watch in Denali Therapeutics Inc. stockWeekly Risk Report & Free Community Supported Trade Ideas - Улправда
15 Most Promising Mid-Cap Healthcare Stocks Under $50 - Insider Monkey
Is Denali Therapeutics Inc. stock a good choice for value investorsWeekly Volume Report & Expert Curated Trade Setup Alerts - Улправда
Precision Trading with Denali Therapeutics Inc. (DNLI) Risk Zones - Stock Traders Daily
Analyst Downgrade: Will Denali Therapeutics Inc. stock reach all time highs in 2025Weekly Market Report & Daily Stock Trend Watchlist - Улправда
Is Denali Therapeutics Inc. stock positioned for digital transformation2025 Market Trends & Daily Volume Surge Signals - Улправда
What insider trading reveals about Denali Therapeutics Inc. stock2025 AllTime Highs & Fast Gain Swing Alerts - Улправда
Can Denali Therapeutics Inc. (4DN) stock sustain institutional flowsQuarterly Trade Summary & Free Risk Controlled Daily Trade Plans - Улправда
What dividend safety score for Denali Therapeutics Inc. stockJuly 2025 Big Picture & High Accuracy Investment Signals - DonanımHaber
Is Denali Therapeutics Inc. (4DN) stock a good hedge against inflationEarnings Growth Summary & Low Risk High Win Rate Picks - DonanımHaber
Is Denali Therapeutics Inc. stock recession proof2025 Support & Resistance & Detailed Earnings Play Strategies - DonanımHaber
What Wall Street predicts for Denali Therapeutics Inc. stock priceEarnings Miss & AI Enhanced Trading Alerts - DonanımHaber
What catalysts could drive Denali Therapeutics Inc. stock higherFed Meeting & Technical Buy Zone Confirmations - Улправда
Does Denali Therapeutics' (DNLI) Discounted Equity Raise Reveal a New Phase in Its Risk Strategy? - simplywall.st
Revenue per share of Denali Therapeutics Inc. – DUS:4DN - TradingView — Track All Markets
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle - The Globe and Mail
Denali Therapeutics (DNLI) funds add $0.01 prefunded warrants in public offering - Stock Titan
Marex Group plc Takes $3.67 Million Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Camber Capital Management LP Has $5.60 Million Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Will Denali's Expanding Pipeline Deliver Breakthroughs In Neurodegenerative Medicine? - RTTNews
Wedbush Issues Pessimistic Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price - MarketBeat
Wedbush Maintains 'Outperform' Rating for DNLI, Lowers Price Tar - GuruFocus
Wedbush Trims Price Target on Denali Therapeutics to $30 From $31, Keeps Outperform Rating - marketscreener.com
Denali Therapeutics dips after pricing $200M equity offering - MSN
Goodwin Advised Royalty Pharma In $275 Million Royalty Funding Agreement With Denali Therapeutics - Mondaq
Denali Therapeutics prices stock offering at $17.50 per share - MSN
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment (DNLI) - Seeking Alpha
Denali Therapeutics (NASDAQ:DNLI) Shares Gap DownHere's What Happened - MarketBeat
Denali Therapeutics Inc (DNLI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Denali Therapeutics Inc 주식 (DNLI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schuth Alexander O. | COFO and Secretary |
Aug 12 '25 |
Sale |
13.58 |
2,937 |
39,884 |
242,346 |
| Ho Carole | Chief Medical Officer |
Aug 12 '25 |
Sale |
13.58 |
2,937 |
39,884 |
217,391 |
| Ho Carole | Chief Medical Officer |
Aug 13 '25 |
Sale |
14.64 |
806 |
11,800 |
216,585 |
0.57%
자본화:
|
볼륨(24시간):